P
ProHub
English 简体中文 繁體中文
Medium M&A

Sternofi

#Pharmaceutical
ProHub Comment

This is a quantitative M&A case requiring candidates to build a market sizing model and conduct a financial break-even analysis. The case tests algebra skills and structured thinking, with the key challenge being organizing complex market share relationships into a coherent analytical framework. The ambiguous conclusion allows for either recommendation if logically supported, emphasizing that real-world business decisions often involve trade-offs rather than clear-cut answers.

Estimated Time 15 minutes
Difficulty Medium
Source NYU
50 / 100
Hamilton & Hamilton (H&H), a multinational pharmaceutical company, is considering acquiring Sternofi, a biotechnology company with a promising drug candidate in phase 2 clinical trials called Deanraghutumab. Should H&H go through with this acquisition?

Clarifying Information

  1. The drug candidate treats pancreatic cancer.
  2. Sternofi has several other drugs in its pipeline, but they are in earlier stages of development and it is too hard to predict how successful they will be at this point.
  3. Clinical trial data suggests Deanraghutumab may be more efficacious than the current standard of care, though, like many cancer drugs, it cannot treat 100% of cases.
  4. Focus only on the US market.
  5. H&H has few oncology products and is looking to expand into that therapeutic area.